Key result
Glimepiride produced similar decreases in fasting plasma glucose and HbA1C compared to glyburide, but with a lower incidence of hypoglycemia.
Why the study?
Does glimepiride improve glycemic control (fasting plasma glucose and HbA1C) compared to glyburide in patients with NIDDM?
Population
577 patients with non-insulin dependent diabetes mellitus (NIDDM)
Comparison
Glimepiride (titration) vs Non-micronized glyburide
Design
RCT, Randomized, parallel-group, Double-blind
Follow-up
1 year
Authors
Loading...
Supports preferring glimepiride to minimize hypoglycemia in NIDDM; confirms comparable efficacy with a safer profile versus glyburide.
RCT (n=577)
Double-blind
parallel-group
Yes
Does glimepiride improve glycemic control (fasting plasma glucose and HbA1C) compared to glyburide in patients with NIDDM?
Glimepiride provides similar glycemic control to glyburide in NIDDM patients but with a lower risk of hypoglycemia.
Dills et al. (1996) conducted an RCT in non-insulin dependent diabetes mellitus (NIDDM) (n=577). Glimepiride vs. Non-micronized glyburide was evaluated on Fasting plasma glucose and HbA1C. Glimepiride produced similar decreases in fasting plasma glucose and HbA1C compared to glyburide, but with a lower incidence of hypoglycemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: